Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial.

Kenneth G SaagMichael A BeckerWilliam B WhiteAndrew WheltonJeffrey S BorerPhilip B GorelickBarbara HuntMajin CastilloLhanoo Gunawardhananull null

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2022)

In the CARES trial, febuxostat and allopurinol (≤600 mg doses) had comparable efficacy in patients with gout and CV disease, and there was no evidence of a relationship between death from CV causes and serum urate levels, number of gout flares, or tophus resolution among the patients receiving febuxostat.

Keyphrases

uric acid
phase iii
study protocol
clinical trial
phase ii
metabolic syndrome
randomized controlled trial
open label
single molecule
type diabetes